Yohimbine Inhibits PDGF-Induced Vascular Smooth Muscle Cell Proliferation and Migration via FOXO3a Factor

Leejin Lim,Hyeonhwa Kim,Jihye Jeong,Sung Hee Han,Young-Bob Yu,Heesang Song
DOI: https://doi.org/10.3390/ijms25136899
IF: 5.6
2024-06-25
International Journal of Molecular Sciences
Abstract:Yohimbine (YHB) has been reported to possess anti-inflammatory, anticancer, and cardiac function-enhancing properties. Additionally, it has been reported to inhibit the proliferation, migration, and neointimal formation of vascular smooth muscle cells (VSMCs) induced by platelet-derived growth factor (PDGF) stimulation by suppressing the phospholipase C-gamma 1 pathway. However, the transcriptional regulatory mechanism of YHB controlling the behavior of VSMCs is not fully understood. In this study, YHB downregulated the expression of cell cycle regulatory proteins, such as proliferating cell nuclear antigen (PCNA), cyclin D1, cyclin-dependent kinase 4 (CDK4), and cyclin E, by modulating the transcription factor FOXO3a in VSMCs induced by PDGF. Furthermore, YHB decreased p-38 and mTOR phosphorylation in a dose-dependent manner. Notably, YHB significantly reduced the phosphorylation at Y397 and Y925 sites of focal adhesion kinase (FAK), and this effect was greater at the Y925 site than Y397. In addition, the expression of paxillin, a FAK-associated protein known to bind to the Y925 site of FAK, was significantly reduced by YHB treatment in a dose-dependent manner. A pronounced reduction in the migration and proliferation of VSMCs was observed following co-treatment of YHB with mTOR or p38 inhibitors. In conclusion, this study shows that YHB inhibits the PDGF-induced proliferation and migration of VSMCs by regulating the transcription factor FOXO3a and the mTOR/p38/FAK signaling pathway. Therefore, YHB may be a potential therapeutic candidate for preventing and treating cardiovascular diseases such as atherosclerosis and vascular restenosis.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: to explore how the medicinal plant extract yohimbine (YHB) inhibits the proliferation and migration of platelet - derived growth factor (PDGF - BB) - induced vascular smooth muscle cells (VSMCs) by regulating the transcription factor FOXO3a and the mTOR/p38/FAK signaling pathway. Specifically, the study aims to reveal the potential therapeutic role of YHB in cardiovascular diseases such as atherosclerosis and restenosis. ### Background and the Importance of the Problem - **Cardiovascular Diseases**: Abnormal proliferation and migration of vascular smooth muscle cells are important factors leading to cardiovascular diseases (such as restenosis and atherosclerosis). - **The Role of PDGF**: PDGF promotes the proliferation and migration of VSMCs by activating multiple signaling pathways (such as p38 and mTOR in the MAPK family). - **The Current Research Status of YHB**: Although previous studies have shown that YHB can prevent the proliferation and migration of VSMCs by inhibiting the PLC - γ1 pathway, its specific molecular mechanism is not yet fully understood. ### Research Objectives - **Main Objective**: To clarify how YHB inhibits PDGF - BB - induced VSMCs proliferation and migration by regulating the FOXO3a transcription factor and the mTOR/p38/FAK signaling pathway. - **Specific Objectives**: - To determine the inhibitory effect of YHB on PDGF - BB - induced VSMCs proliferation and migration. - To explore the influence of YHB on the expression of cell cycle regulatory proteins (such as PCNA, cyclin D1, CDK4 and cyclin E). - To verify whether YHB inhibits the proliferation and migration of VSMCs by regulating the FOXO3a transcription factor. - To analyze the influence of YHB on FAK - related proteins (such as paxillin) and the mTOR/p38 signaling pathway. - To evaluate the synergistic inhibitory effect of YHB in combination with mTOR and p38 inhibitors on VSMCs proliferation and migration. ### Research Methods - **Cell Experiments**: Use VSMCs for in vitro experiments, including cell viability assay (MTT), cell proliferation assay (BrdU), cell migration assay (scratch test and Boyden chamber test). - **Molecular Biology Techniques**: Detect the expression and phosphorylation levels of cell cycle regulatory proteins, FOXO3a, p38, mTOR and FAK - related proteins by Western blotting, immunofluorescence and flow cytometry (FACS). ### Main Findings - **YHB Inhibits VSMCs Proliferation and Migration**: YHB significantly inhibits PDGF - BB - induced VSMCs proliferation and migration at a concentration of 10 - 50 µM. - **Cell Cycle Regulation**: YHB inhibits VSMCs proliferation by arresting cells in the G0/G1 phase and inhibiting the expression of cell cycle regulatory proteins (such as PCNA, cyclin D1, CDK4 and cyclin E). - **Regulation of FOXO3a**: YHB inhibits the proliferation and migration of VSMCs by down - regulating the expression of FOXO3a. - **Influence on Signaling Pathways**: YHB significantly inhibits PDGF - BB - induced phosphorylation of FAK (especially at the Y925 site) and mTOR/p38, but has no obvious effect on the phosphorylation of ERK and Akt. - **Synergistic Inhibitory Effect**: When YHB is used in combination with mTOR or p38 inhibitors, it has a stronger inhibitory effect on the proliferation and migration of VSMCs, especially when used in combination with p38 inhibitors. ### Conclusions - **The Potential Therapeutic Role of YHB**: YHB inhibits PDGF - BB - induced VSMCs proliferation and migration by regulating the FOXO3a transcription factor and the mTOR/p38/FAK signaling pathway, and may become a potential candidate drug for the prevention and treatment of cardiovascular diseases.